Gilead Stock News

Nexus Investment Management ULC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% in the 3rd quarter, Holdings Channel reports. The fund owned 312,318 shares of the biopharmaceutical companys stock after selling 3,078 shares during the period. Gilead Sciences accounts for 2.4% of Nexus Investment Management ULCs holdings, making the stock its 22nd biggest []

The sexually transmitted diseases (STDs) denotes to a varied clinical syndromes and infections initiated by pathogens that can be developed and spread through sexual activity. The STDs are detected through various tests such as physical examination or assays, rapid plasma

BDO Wealth Advisors LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,790 shares of the biopharmaceutical companys stock after selling 601 shares during the quarter. BDO Wealth Advisors []

Thomasville National Bank raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 123,820 shares of the biopharmaceutical companys stock after purchasing an additional 7,081 shares during the period. Thomasville []

Confluence Investment Management LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,224,499 shares of the biopharmaceutical companys stock after buying an additional 10,684 shares during the quarter. Confluence Investment Management LLCs []

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

The mutated version of the virus exhibited resistance to the antiviral drug remdesivir.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new clinical and real-world data at the American Association for the Study of Liver Disea

Gritstone Poised To Dominate mRNA Market

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

A blowout third quarter did little to ignite the shares of Gilead Sciences Inc. ( GILD , Financial) as investors seemed to be spooked by concerns over the staying power of the company's antiviral drug

Gilead Is A Solidly Profitable, High Dividend-Yielding Stock